Roche Holding AG has high hopes for the investigational COVID-19 antibody cocktail from Regeneron Pharmaceuticals, Inc. it is helping to develop but Bill Anderson, head of pharma at the Swiss major, has warned that even if REGN-COV2 gets approval, demand will far outstrip supply.
REGN-COV2, a combination of two antibodies (REGN10933 and REGN10987) has been much in the news since doctors administered the treatment to President Trump when he was diagnosed with coronavirus infection earlier this month and subsequently claimed it as a cure
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?